Indication

extraadrenal

1 clinical trial

1 product

Clinical trial

A Phase 2 Study of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Status: Recruiting, Estimated PCD: 2023-10-17

Product